{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:39Z","timestamp":1788250479528,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejca.2021.11.019","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T13:14:49Z","timestamp":1641302089000},"page":"138-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies"],"prefix":"10.1016","volume":"162","author":[{"given":"Morgane","family":"Stouvenot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Meurisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Saint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Buecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Jary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"El Hajbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Baba-Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Desrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Zoubir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Parzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamadi","family":"Almotlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Vienot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Jacquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.11.019_bib1","first-page":"7","article-title":"Cancers statistic, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.ejca.2021.11.019_bib2","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2021.11.019_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.11.019_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study","volume":"129","author":"Abramowitz","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2021.11.019_bib5","series-title":"SEER cancer statistics factsheets: anal cancer","year":"2020"},{"key":"10.1016\/j.ejca.2021.11.019_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib7","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","article-title":"DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib8","article-title":"Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol. janv"},{"key":"10.1016\/j.ejca.2021.11.019_bib9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1634\/theoncologist.2016-0241","article-title":"Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients","volume":"22","author":"Sclafani","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.11.019_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000361051","article-title":"Carboplatin and placlitaxel treatment is effective in advanced anal cancer","volume":"87","author":"Kim","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2021.11.019_bib11","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1002\/cam4.2558","article-title":"Mitomycin and 5-fluorouracil for second-line treatment metastatic squamous cell carcinomas of the anal canal","volume":"8","author":"Saint","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.019_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib13","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib14","series-title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC)\u202f: results from the multicohort, phase II Keynote-158 study","first-page":"1","volume":"38 (4_suppl)","author":"Marabelle","year":"2020"},{"key":"10.1016\/j.ejca.2021.11.019_bib15","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma\u202f: pooled results from the Keynote-028 and Keynote-158 studies","volume":"38 (15_suppl)","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib16","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2272","article-title":"LBA42 POD1UM-202: phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy","volume":"31","author":"Rao","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/s12885-017-3566-0","article-title":"Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2021.11.019_bib18","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.513","article-title":"Final results of the CARACAS study\u202f: randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment","volume":"31","author":"Lonardi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib19","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.514","article-title":"Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.019_bib20","first-page":"3783","article-title":"Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas","volume":"59","author":"Harada","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2021.11.019_bib21","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.019_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumour-specific vaccine for patients with incurable human papillomavirus 16\u2013related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2021.11.019_bib23","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-12-0896","article-title":"Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumour","volume":"18","author":"Dosset","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.ejca.2021.11.019_bib24","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.3390\/ijms21186838","volume":"21","author":"Spehner","year":"2020","journal-title":"IJMS"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.019_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1158\/2326-6066.CIR-19-0326","article-title":"Immunoregulation and clinical implications of ANGPT2\/TIE2 + M-MDSC signature in non\u2013small cell lung cancer","volume":"8","author":"Lauret Marie Joseph","year":"2020","journal-title":"Cancer Immunol Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:25Z","timestamp":1760733325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":25,"alternative-id":["S0959804921012302"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}